Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection

View ORCID ProfileMichael J. Peluso, Scott Lu, Alex F. Tang, View ORCID ProfileMatthew S. Durstenfeld, Hsi-en Ho, Sarah A. Goldberg, Carrie A. Forman, Sadie E. Munter, Rebecca Hoh, Viva Tai, Ahmed Chenna, Brandon C. Yee, John W. Winslow, Christos J. Petropoulos, Bryan Greenhouse, Peter W. Hunt, Priscilla Y. Hsue, Jeffrey N. Martin, J. Daniel Kelly, David V. Glidden, View ORCID ProfileSteven G. Deeks, Timothy J. Henrich
doi: https://doi.org/10.1101/2021.07.09.21260287
Michael J. Peluso
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael J. Peluso
  • For correspondence: michael.peluso@ucsf.edu
Scott Lu
2Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex F. Tang
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew S. Durstenfeld
3Division of Cardiology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew S. Durstenfeld
Hsi-en Ho
4Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah A. Goldberg
2Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carrie A. Forman
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sadie E. Munter
5Division of Experimental Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Hoh
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viva Tai
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed Chenna
6Monogram Biosciences Inc., South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandon C. Yee
6Monogram Biosciences Inc., South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Winslow
6Monogram Biosciences Inc., South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos J. Petropoulos
6Monogram Biosciences Inc., South San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Greenhouse
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter W. Hunt
5Division of Experimental Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priscilla Y. Hsue
3Division of Cardiology, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey N. Martin
2Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Daniel Kelly
2Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David V. Glidden
2Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven G. Deeks
1Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven G. Deeks
Timothy J. Henrich
5Division of Experimental Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND The biological processes associated with post-acute sequelae of SARS-CoV-2 infection (PASC) are unknown.

METHODS We measured soluble markers of inflammation in a SARS-CoV-2 recovery cohort at early (<90 days) and late (>90 days) timepoints. We defined PASC as the presence of one or more COVID-19-attributed symptoms beyond 90 days. We compared fold-changes in marker values between those with and without PASC using mixed effects models with terms for PASC and early and late recovery time periods.

RESULTS During early recovery, those who went on to develop PASC generally had higher levels of cytokine biomarkers including TNF-alpha (1.14-fold higher mean ratio, 95%CI 1.01-1.28, p=0.028) and IP-10 (1.28-fold higher mean ratio, 95%CI 1.01-1.62, p=0.038). Among those with PASC, there was a trend toward higher IL-6 levels during early recovery (1.28-fold higher mean ratio, 95%CI 0.98- 1.70, p=0.07) which became more pronounced in late recovery (1.44-fold higher mean ratio, 95%CI: 1.11-1.86, p<0.001). These differences were more pronounced among those with a greater number of PASC symptoms.

CONCLUSIONS Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing PASC.

Competing Interest Statement

AC, BCY, JWW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCorp. DVG reports grants and/or personal fees from Merck and Co. and Gilead Biosciences outside the submitted work. SGD reports grants and/or personal fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian Biosciences outside the submitted work. TJH reports grants from Merck and Co., Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work. The remaining authors report no conflicts.

Clinical Trial

NCT04362150

Funding Statement

This work was supported by the National Institute of Allergy and Infectious Diseases (NIH/NIAID 3R01AI141003-03S1 [to TJ Henrich] and by the Zuckerberg San Francisco Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine. MJP is supported on NIH T32 AI60530-12 and by the UCSF Resource Allocation Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants provided written informed consent. The study was approved by the Institutional Review Board at the University of California, San Francisco.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be made available when the analysis is complete.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted July 11, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection
Michael J. Peluso, Scott Lu, Alex F. Tang, Matthew S. Durstenfeld, Hsi-en Ho, Sarah A. Goldberg, Carrie A. Forman, Sadie E. Munter, Rebecca Hoh, Viva Tai, Ahmed Chenna, Brandon C. Yee, John W. Winslow, Christos J. Petropoulos, Bryan Greenhouse, Peter W. Hunt, Priscilla Y. Hsue, Jeffrey N. Martin, J. Daniel Kelly, David V. Glidden, Steven G. Deeks, Timothy J. Henrich
medRxiv 2021.07.09.21260287; doi: https://doi.org/10.1101/2021.07.09.21260287
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection
Michael J. Peluso, Scott Lu, Alex F. Tang, Matthew S. Durstenfeld, Hsi-en Ho, Sarah A. Goldberg, Carrie A. Forman, Sadie E. Munter, Rebecca Hoh, Viva Tai, Ahmed Chenna, Brandon C. Yee, John W. Winslow, Christos J. Petropoulos, Bryan Greenhouse, Peter W. Hunt, Priscilla Y. Hsue, Jeffrey N. Martin, J. Daniel Kelly, David V. Glidden, Steven G. Deeks, Timothy J. Henrich
medRxiv 2021.07.09.21260287; doi: https://doi.org/10.1101/2021.07.09.21260287

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)